Summary
0.29 -0.00(-1.29%)09/18/2024
Renalytix AI Plc (RNLX)
Renalytix AI Plc (RNLX)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-0.34 | 0.21 | -28.43 | -41.69 | -72.31 | -86.29 | 0.00 | -97.85 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 0.29 | |
Open | 0.30 | |
High | 0.30 | |
Low | 0.28 | |
Volume | 96,072 | |
Change | -0.00 | |
Change % | -0.34 | |
Avg Volume (20 Days) | 1,393,265 | |
Volume/Avg Volume (20 Days) Ratio | 0.07 | |
52 Week Range | 0.22 - 2.40 | |
Price vs 52 Week High | -87.89% | |
Price vs 52 Week Low | 32.14% | |
Range | -1.92 | |
Gap Up/Down | 0.00 |
Fundamentals | ||
Market Capitalization (Mln) | 21 | |
EBIDTA | 0 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 35.00 | |
Book Value | 1.6600 | |
Earnings Per Share | -1.0440 | |
EPS Estimate Current Quarter | 0.0000 | |
EPS Estimate Next Quarter | 0.0000 | |
EPS Estimate Current Year | -0.3500 | |
EPS Estimate Next Year | -0.3300 | |
Diluted EPS (TTM) | -1.0440 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | -19.7162 | |
Return on asset (TTM) | -0.3069 | |
Return on equity (TTM) | -0.5143 | |
Revenue TTM | 1,973,000 | |
Revenue per share TTM | 0.0540 | |
Quarterly Revenue Growth (YOY) | 0.0000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 633,000 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 9.4767 | |
Revenue Enterprise Value | 245.6233 | |
EBITDA Enterprise Value | 0.0000 | |
Shares | ||
Shares Outstanding | 36,154,500 | |
Shares Float | 32,690,003 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 0.00 | |
Institutions (%) | 17.87 |
07/11 07:00 EST - globenewswire.com
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno'), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices.
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno'), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices.
06/27 18:30 EST - globenewswire.com
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”
06/14 07:00 EST - globenewswire.com
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage
05/15 18:15 EST - seekingalpha.com
Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript
Renalytix Plc (NASDAQ:RNLX ) Q3 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer James Sterling - Chief Financial Officer Howard Doran - Chief Business Officer Conference Call Participants Dan Arias - Stifel Randy Baron - Pinnacle Associates Mark Massaro - BTIG Jens Lindqvist - Investec Operator Good morning, and welcome to the Renalytix conference call to review Third Quarter Fiscal Year 2024 Financial Results. [Operator Instructions].
Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript
Renalytix Plc (NASDAQ:RNLX ) Q3 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer James Sterling - Chief Financial Officer Howard Doran - Chief Business Officer Conference Call Participants Dan Arias - Stifel Randy Baron - Pinnacle Associates Mark Massaro - BTIG Jens Lindqvist - Investec Operator Good morning, and welcome to the Renalytix conference call to review Third Quarter Fiscal Year 2024 Financial Results. [Operator Instructions].
05/15 07:00 EST - globenewswire.com
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024.
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024.
05/09 07:00 EST - globenewswire.com
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day.
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day.
04/08 07:00 EST - globenewswire.com
Renalytix Announces Financing with Expected Size of up to $4 Million
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseases care. The Fundraise was conducted by way of a securities purchase agreement between the Purchaser and the Company which consists of an initial tranche of 2,666,667 Ordinary Shares initially for an amount of $1.0 million (the “Initial Tranche Shares”) with an optional subsequent tranche of Ordinary Shares at the option of the Purchaser. Both tranches are priced at $0.75 per NASDAQ ADS ($0.375 per Ordinary Share). The aggregate total amount for both tranches, if the option is fully exercised, is expected to be up to $4 million in total financing. The net proceeds of the Fundraise will be used to support commercial sales activity as the Company continues its Formal Sale Process, as previously announced.
Renalytix Announces Financing with Expected Size of up to $4 Million
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseases care. The Fundraise was conducted by way of a securities purchase agreement between the Purchaser and the Company which consists of an initial tranche of 2,666,667 Ordinary Shares initially for an amount of $1.0 million (the “Initial Tranche Shares”) with an optional subsequent tranche of Ordinary Shares at the option of the Purchaser. Both tranches are priced at $0.75 per NASDAQ ADS ($0.375 per Ordinary Share). The aggregate total amount for both tranches, if the option is fully exercised, is expected to be up to $4 million in total financing. The net proceeds of the Fundraise will be used to support commercial sales activity as the Company continues its Formal Sale Process, as previously announced.
03/25 15:58 EST - investorplace.com
3 Ridiculously Enticing Stocks to Buy for Under a Buck
Let's keep it real in this joint – you should generally avoid stocks under $1. Yes, they're “cheap” but that's not necessarily a good thing.
3 Ridiculously Enticing Stocks to Buy for Under a Buck
Let's keep it real in this joint – you should generally avoid stocks under $1. Yes, they're “cheap” but that's not necessarily a good thing.
03/14 07:00 EST - globenewswire.com
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
02/15 07:00 EST - globenewswire.com
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023. The Company plans to issue another announcement following today's report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events.
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023. The Company plans to issue another announcement following today's report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events.
02/15 06:38 EST - proactiveinvestors.com
Renalytix slides by a third as funding moves front and centre
Renalytix dropped by more than a third as its latest interim results show more big losses and a shrinking cash pile. Losses are inevitable for an early-stage company such as Renalytix, which is developing diagnostics tools for kidney illness sufferers, but the scale seemingly is raising some alarms.
Renalytix slides by a third as funding moves front and centre
Renalytix dropped by more than a third as its latest interim results show more big losses and a shrinking cash pile. Losses are inevitable for an early-stage company such as Renalytix, which is developing diagnostics tools for kidney illness sufferers, but the scale seemingly is raising some alarms.
02/09 09:00 EST - globenewswire.com
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG.
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG.
02/09 05:44 EST - proactiveinvestors.com
Renalytix rises on draft Medicare determination
Shares in Renalytix PLC (AIM:RENX) jumped almost 30% on Friday after the diagnostics firm revealed a draft Medicare determination for its kidney function tests. The Centers for Medicare and Medicaid Services published the draft local coverage determination on Thursday, Renalytix said, relating to the use of its tests for those on the US state-funded medical insurance programme.
Renalytix rises on draft Medicare determination
Shares in Renalytix PLC (AIM:RENX) jumped almost 30% on Friday after the diagnostics firm revealed a draft Medicare determination for its kidney function tests. The Centers for Medicare and Medicaid Services published the draft local coverage determination on Thursday, Renalytix said, relating to the use of its tests for those on the US state-funded medical insurance programme.
01/10 07:00 EST - globenewswire.com
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months
11/14 11:18 EST - seekingalpha.com
Renalytix Plc (RNLX) Q1 2024 Earnings Call Transcript
Renalytix Plc (NASDAQ:RNLX ) Q1 2024 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Howard Doran - Chief Business Officer Tom McLain - President James Sterling - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Randy Baron - Pinnacle Associates Jens Lindqvist – Investec Operator Good morning, ladies and gentlemen, and welcome to Renalytix Conference Call to Review First Quarter Fiscal Year 2024 Financial Results. At this time, all participants are in a listen-only mode.
Renalytix Plc (RNLX) Q1 2024 Earnings Call Transcript
Renalytix Plc (NASDAQ:RNLX ) Q1 2024 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Howard Doran - Chief Business Officer Tom McLain - President James Sterling - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Randy Baron - Pinnacle Associates Jens Lindqvist – Investec Operator Good morning, ladies and gentlemen, and welcome to Renalytix Conference Call to Review First Quarter Fiscal Year 2024 Financial Results. At this time, all participants are in a listen-only mode.
11/14 07:00 EST - globenewswire.com
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2023.
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2023.
11/07 07:00 EST - globenewswire.com
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
10/26 07:31 EST - zacks.com
New Strong Buy Stocks for October 26th
GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.
New Strong Buy Stocks for October 26th
GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.
10/16 13:32 EST - zacks.com
What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy Stock
Renalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy Stock
Renalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
10/12 09:01 EST - zacks.com
New Strong Buy Stocks for October 12th
BTE, AZEK, SOLO, RNLX and RSKD have been added to the Zacks Rank #1 (Strong Buy) List on October 12, 2023.
New Strong Buy Stocks for October 12th
BTE, AZEK, SOLO, RNLX and RSKD have been added to the Zacks Rank #1 (Strong Buy) List on October 12, 2023.